Elafibranor治疗原发性硬化性胆管炎的安全性与疗效:ELMWOOD II期随机对照试验
ELMWOOD II期双盲随机对照试验纳入68例碱性磷酸酶≥1.5倍正常上限的原发性硬化性胆管炎成人患者,随机接受Elafibranor 80 mg、120 mg或安慰剂治疗12周。主要终点为安全性;与安慰剂相比,Elafibranor两剂量组碱性磷酸酶相对基线均下降,120 mg组应答幅度大于80 mg组,药物耐受性良好。
要点
- Elafibranor 80 mg和120 mg组12周碱性磷酸酶较安慰剂分别降低35.3%和54.7%(最小二乘均值治疗差异)。
- 碱性磷酸酶正常化仅见于Elafibranor 80 mg组(9.1%)和120 mg组(17.4%),安慰剂组无。
- 治疗中出现的不良事件发生率80 mg组68.2%、120 mg组78.3%、安慰剂组69.6%,严重不良事件仅见于安慰剂组(4.3%)。
核心结论
- Elafibranor在原发性硬化性胆管炎患者中耐受性良好,与安慰剂相比12周内生化指标改善更大。
- Elafibranor 120 mg组的应答幅度大于80 mg组。
- 作者认为这些发现支持开展更大规模、更长疗程的研究以探索Elafibranor治疗原发性硬化性胆管炎的潜力。
研究设计与样本
- ELMWOOD为12周双盲II期随机对照试验(NCT05627362),纳入碱性磷酸酶≥1.5倍正常上限的原发性硬化性胆管炎成人患者。
- 共68例参与者随机分配至Elafibranor 80 mg组(n=22)、Elafibranor 120 mg组(n=23)或安慰剂组(n=23)。
- 参与者男性占54.4%,平均年龄46.3岁,合并炎症性肠病者占55.9%;基线时70.6%使用熊去氧胆酸,48.5%的ELF评分>9.8,平均碱性磷酸酶水平为369.5 U/L。
- 主要终点为Elafibranor相较于安慰剂的安全性;其他终点包括碱性磷酸酶和增强肝纤维化(ELF)评分相对基线的平均变化。
主要发现
- 第12周时,Elafibranor 80 mg组、120 mg组和安慰剂组治疗中出现的不良事件发生率分别为68.2%、78.3%和69.6%。
- 导致停药的治疗中出现的不良事件发生率在80 mg组为4.5%、120 mg组为4.3%、安慰剂组为8.7%。
- 严重治疗中出现的不良事件仅见于安慰剂组(4.3%)。
- 与安慰剂相比,Elafibranor 80 mg组和120 mg组碱性磷酸酶的最小二乘均值治疗差异(95% CI)分别为-35.3%(-49.2,-21.4)和-54.7%(-68.3,-41.0)。
- 碱性磷酸酶正常化仅见于Elafibranor 80 mg组(9.1%)和120 mg组(17.4%);ELF评分相对基线变化的最小二乘均值治疗差异(95% CI)在80 mg组为-0.19(-0.52,+0.15)、120 mg组为-0.28(-0.62,+0.06)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Primary sclerosing cholangitis (PSC) is a rare, chronic liver disease. Elafibranor, a dual peroxisome proliferator-activated receptor-α/δ agonist, was investigated in the phase II ELMWOOD trial (NCT05627362). METHODS: This 12-week, double-blind trial enrolled adults with PSC and alkaline phosphatase (ALP) ≥1.5× the upper limit of normal. The primary endpoint was elafibranor safety vs. placebo. Additional endpoints included relative mean change from baseline in ALP and enhanced liver fibrosis (ELF) score. RESULTS: A total of 68 participants (male: 54.4%; mean age: 46.3 years; inflammatory bowel disease: 55.9%) were randomized to elafibranor 80 mg (n = 22), elafibranor 120 mg (n = 23), or placebo (n = 23). At baseline, 70.6% were on ursodeoxycholic acid, 48.5% had ELF scores >9.8, and the mean ALP level was 369.5 U/L. At Week 12, rates of treatment-emergent adverse events (TEAEs) and TEAEs leading to discontinuation in participants on elafibranor 80 mg, 120 mg, and placebo were 68.2%, 78.3%, and 69.6%, and 4.5%, 4.3%, and 8.7%, respectively. Serious TEAEs occurred only in participants on placebo (4.3%). Participants on elafibranor 80 mg and 120 mg had reductions in ALP vs. placebo (least squares mean treatment difference [95% CI]: -35.3% [-49.2, -21.4] and -54.7% [-68.3, -41.0], respectively). ALP normalization occurred only in participants on elafibranor 80 mg (9.1%) and 120 mg (17.4%). The LS mean treatment differences (95% CI) in change from baseline in ELF scores in participants on elafibranor 80 mg and 120 mg vs. placebo were -0.19 (-0.52, +0.15) and -0.28 (-0.62, +0.06), respectively. CONCLUSIONS: Elafibranor was well tolerated in people with PSC and associated with greater biochemical improvements over 12 weeks compared with placebo. A greater magnitude of response was observed with elafibranor 120 mg compared with 80 mg. IMPACT AND IMPLICATIONS: For people with primary sclerosing cholangitis (PSC), there is a need for a well-tolerated and effective treatment that will enhance quality of life, prevent disease progression, and improve long-term outcomes. Here, we present results from the double-blind period of the phase II ELMWOOD trial in PSC, wherein elafibranor, a peroxisome proliferator-activated receptor-α/δ agonist, demonstrated a favorable safety profile, provided greater biochemical improvements over 12 weeks compared with placebo, and appeared to stabilize markers of fibrosis and improve pruritus. These findings support larger and longer term investigations of elafibranor to explore its therapeutic potential as a treatment for people with PSC.
引用
- Levy C, Abouda GF, Bilir BM, et al. Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial. J Hepatol. 2025. PMID: 40350321. doi:10.1016/j.jhep.2025.04.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。